The nicotinic acetylcholine receptor, smoking, and Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 4, Issue 4, 2002, Pages 317-325

  Sabbagha, Marwan N ^a   Lukas, Ronald J ^a   Sparks, D Larry ^a   Reid, Richard T ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; AMYLOID PRECURSOR PROTEIN; CHOLINE ACETYLTRANSFERASE; MESSENGER RNA; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR;

ALZHEIMER DISEASE; CLINICAL FEATURE; COGNITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NEUROCHEMISTRY; NEUROPROTECTION; PRIORITY JOURNAL; REVIEW; SMOKING;

EID: 0036669581     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/jad-2002-4407     Document Type: Review

References (109)

1. E. Albuquerque, M. Alkondon, E. Pereira, N. Castro, A. Schrattenholz, C. Barbosa et al., Properties of neuronal nicotinic acetylcholine receptors, pharmacological characterization and modulation of synaptic function, J Pharmacol Exp Ther 280 (1996), 1117-1136.
2. E. Albuquerque, E. Pereira, M. Alkondon, H. Eisenberg and A. Maelicke, Neuronal Nicotinic Receptors and Synaptic Transmission in the Mammalian Central Nervous System, Berlin Springer, pp. 337-358.
3. I. Aubert, D.M. Araujo, D. Cecyre, Y. Robitaille, S. Gauthier and R. Quirion, Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases, J Neurochem 58 (1992), 529-541.
4. C. Banerjee, J.R. Nyengaard, A. Wevers, R.A. de Vos, E.N. Jansen Steur, J. Lindstrom, K. Pilz, S. Nowacki, W. Bloch et al., Cellular expression of alpha7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease - A stereological approach, Neurobiol Dis 7, (2000), 666-72.
5. M. Bencherif, K. Fowler, R.J. Lukas and P.M. Lippiello, Mechanisms of up-regulation of neuronal nicotinic acetylcholine receptors in clonal cell lines and primary cultures of fetal rat brain, J Pharmacol Exp Ther 275 (1995), 987-994.
6. M. Benwell, D. Balfour and J. Anderson, Evidence that tobacco smoking increases the density of nicotine binding sites in human brain, J Neurochem 50 (1988), 1243-1247.
7. C.R. Breese, C. Adams, J. Logel, C. Drebing, Y. Rollins, M. Barnhart, B. Sullivan, B.K. Demasters, R. Freedman et al., Comparison of the regional expression of nicotinic acetylcholine receptor alpha7 mRNA and, J Comp Neurol 387 (1997), 385-398.
8. D.E. Brenner, W.A. Kukull, G. van Belle, J.D. Bowen, W.C. McCormick, L. Teri and E.B. Larson, Relationship between cigarette smoking and Alzheimer's disease in a population-based case-control study, Neurology 43 (1993), 293-300.
9. D. Carmelli, G.E. Swan, T. Reed, G.D. Schellenberg and J.C. Christian, The effect of apolipoprotein E epsilon4 in the relationships of smoking and drinking to cognitive function, Neuroepidemiology 18 (1999), 125-133.
10. A.C. Collins and M. Marks, Are nicotinic acetylcholine receptors activated or inhibited following chronic nicotine treatment? Drug Dev Res 38 (1996), 231-242.
11. J. Court, C. Martin-Ruiz, M. Piggott, D. Spurden, M. Griffiths and E. Perry, Nicotinic receptor abnormalities in Alzheimer's disease, Biol Psychiatry 49 (2001), 175-184.
12. P. Davies and S. Feisullin, Postmortem stability of alpha-bungarotoxin binding sites in mouse and human brain, Brain Res 216 (1981), 449-454.
13. K.L. Davis and H.I. Yamamura, Cholinergic under-activity in human memory disorders, Life Sci 23 (1978), 1729-1733.
14. M. Defever, Long term care: The case of the elderly, Health Policy 19 (1991), 1-18.
15. S.T. DeKosky and S.W. Scheff, Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity, Ann Neurol 27 (1990), 457-464.
16. K.T. Dineley, M. Westerman, D. Bui, K. Bell, K.H. Ashe and J.D. Sweatt, Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease, J Neurosci 21 (2001), 4125-4133.
17. R. Doll, R. Peto, J. Boreham and I. Sutherland, Smoking and dementia in male British doctors: Prospective study, BMJ 320 (2000), 1097-1102.
18. D.L. Donnelly-Roberts, I.C. Xue, S.P. Americ and J.P. Sullivan, In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418, Brain Res 719 (1996), 36-44.
19. D. Edwards, R. Deuel, C. Baum and J. Morris, A quantitative analysis of apraxia in senile dementia of the Alzheimer type: Stage-related differences in prevalence and type, Dementia 2, 142-149.
20. S. Efthimiopoulos, D. Vassilacopoulou, J.A. Ripellino, N. Tezapsidis and N.K. Robakis, Cholinergic agonists stimulate secretion of soluble full-length amyloid precursor protein in neuroendocrine cells, Proc Natl Acad Sci USA 93 (1996), 8046-8050.
21. D.D. Flynn and D.C. Mash, Characterization of L-[3H]nicotine binding in human cerebral cortex: Comparison between Alzheimer's disease and the normal, J Neurochem 47 (1986), 1948-1954.
22. E. Giacobini, Nicotine Acetylcholine Receptors in Human Cortex: Aging and Alzheimer's Disease in Lippiello PNM, Raven Press, New York, 1992, pp. 183-194.
23. S.R. Grady, M.J. Marks and A.C. Collins, Desensitization of nicotine-stimulated, J Neurochem 62 (1994), 1390-1398.
24. C.J. Hillard and J.J. Pounds, Effects of chronic nicotine treatment on the accumulation of, J Neurochem 60 (1993), 687- 695.
25. B.A. Hulihan-Giblin, M.D. Lumpkin and K.J. Kellar, Effects of chronic administration of nicotine on prolactin release in the rat: Inactivation of prolactin response by repeated injections of nicotine, J Pharmacol Exp Ther 252 (1990), 21-25.
26. A. Itoh, A. Nitta, M. Nadai, K. Nishimura, M. Hirose, T. Hasegawa and T. Nabeshima, Dysfunction of cholinergic and dopaminergic neuronal systems in beta-amyloid protein-infused rats, J Neurochem 66 (1996), 1113-1117.
27. J.R. James and A. Nordberg, Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: Emphasis on Alzheimer's disease and Parkinson's disease, Behav Genet 25 (1995), 149-159.
28. G.M. Jones, B.J. Sahakian, R. Levy, D.M. Warburton and J.A. Gray, Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease, Psychopharmacology (Berl) 108 (1992), 485-494.
29. L. Ke, C.M. Eisenhour, M. Bencherif and R.J. Lukas, Effects of chronic nicotine treatment on expression of diverse nicotinic acetylcholine receptor subtypes. I. Dose- and time-dependent effects of nicotine treatment, J Pharmacol Exp Ther286 (1998), 825-840.
30. K.J. Kellar, P.J. Whitehouse, A.M. Martino-Barrows, K. Marcus and D.L. Price, Muscarinic and nicotinic cholinergic binding sites in Alzheimer's disease cerebral cortex, Brain Res 436 (1987), 62-68.
31. T. Kihara and S. Shimohama, Nicotinic Agonists Protect Neurons from Glutamate and β-amyloid Neurotoxicity, Springer Publishing, New York, 2000, pp. 217-222.
32. T. Kihara, S. Shimohama and A. Akaike, Effects of nicotinic receptor agonists on beta-amyloid beta-sheet formation, Jpn J Pharmacol 79 (1999), 393-396.
33. T. Kihara, S. Shimohama, H. Sawada, J. Kimura, T. Kume, H. Kochiyama, T. Maeda and A. Akaike, Nicotinic receptor stimulation protects neurons against beta-amyloid toxicity, Ann Neurol 42 (1997), 159-163.
34. T. Kihara, S. Shimohama, S. Sawada, et al., Neuroprotective effect of nicotine against beta amyloid cytotoxicity, Neurobiology of Aging 17 (1996), S429.
35. T. Kihara, S. Shimohama, M. Urushitani, H. Sawada, J. Kimura, T. Kume, T. Maeda and A. Akaike, Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity, Brain Res 792 (1998), 331-334.
36. S.H. Kim, Y.K. Kim, S.J. Jeong, C. Haass, Y.H. Kim and Y.H. Suh, Enhanced release of secreted form of Alzheimer's amyloid precursor protein from PC12 cells by nicotine, Mol Pharmacol 52 (1997), 430-436.
37. W.A. Kukull, The association between smoking and Alzheimer's disease: Effects of study design and bias, Biol Psychiatry 49 (2001), 194-199.
38. P.A. Lapchak, D.M. Araujo, R. Quirion and B. Collier, Effect of chronic nicotine treatment on nicotinic autoreceptor function and N-[3H]methylcarbamylcholine binding sites in the rat brain, J Neurochem 52 (1989), 483-491.
39. E.P. Lapin, H.S. Maker, H. Sershen and A. Lajtha, Action of nicotine on accumbens dopamine and attenuation with repeated administration, Eur J Pharmacol 160 (1989), 53-59.
40. L.J. Launer, K. Andersen and M.E.e.a. Dewey, Rates and risk factors for dementia and Alzheimer's disease: Results from EURODEM pooled analyses, Neurology 52 (1999), 78-84.
41. D. Leibovici, K. Ritchie, B. Ledesert and J. Touchon, The effects of wine and tobacco consumption on cognitive performance in the elderly: A longitudinal study of relative risk, Int J Epidemiol 28 (1999), 77-81.
42. E. Levin, C. Conners and D.e.a. Silva, Transdermal nicotine effects on attention, Psychopharmacology 140 (1998), 135-141.
43. W. Linert, M.H. Bridge, M. Huber, K.B. Bjugstad, S. Grossman and G.W. Arendash, In vitro and in vivo studies investigating possible antioxidant actions of nicotine: Relevance to Parkinson's and Alzheimer's diseases, Biochim Biophys Acta 1454 (1999), 143-152.
44. Q. Liu, H. Kawai and D.K. Berg, beta-Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons, Proc Natl Acad Sci USA 98 (2001), 4734-4739.
45. R. Lukas, Neuronal Nicotinic Acetylcholine Receptors, Springer-Verlag, Berlin, and R.G. Landes Company, Georgetown, Texas, 1998, pp. 145-173.
46. R. Lukas, L. Ke, M. Bencheirf and C. Eisenhoukr, Regulation by nicotine by its own receptors, Drug Dev Res 38 (1996), 136-148.
47. A. Maelicke, M. Samochocki, R. Jostock, A. Fehrenbacher, J. Ludwig, E.X. Albuquerque and M. Zerlin, Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease, Biol Psychiatry 49 (2001), 279-288.
48. P. Marin, M. Maus, S. Desagher, J. Glowinski and J. Premont, Nicotine protects cultured striatal neurones against N-methyl-D-aspartate receptor-mediated neurotoxicity, Neuroreport 5 (1994), 1977-1980.
49. M.J. Marks, S.R. Grady and A.C. Collins, Down-regulation of nicotinic receptor function after chronic nicotine infusion, J Pharmacol Exp Ther 266 (1993), 1268-1276.
50. M.J. Marks, S.R. Grady, J.M. Yang, P.M. Lippiello and A.C. Collins, Desensitization of nicotine-stimulated 86Rb+ efflux from mouse brain synaptosomes, J Neurochem 63 (1994), 2125-2135.
51. C.M. Martin-Ruiz, J.A. Court, E. Molnar, M. Lee, C. Gotti, A. Mamalaki, T. Tsouloufis, S. Tzartos, C. Ballard, et al., Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease, J Neurochem 73 (1999), 1635-1640.
52. C. Merchant, M.X. Tang, S. Albert, J. Manly, Y. Stern and R. Mayeux, The influence of smoking on the risk of Alzheimer's disease, Neurology 52 (1999), 1408-1412.
53. D.M. Morens, A. Grandinetti, D. Reed and L.R. White, Smoking-associated protection from Alzheimer's and Parkinson's disease, Lancet 343 (1994), 356-357.
54. D.M. Morens, A. Grandinetti, D. Reed, L.R. White and G.W. Ross, Cigarette smoking and protection from Parkinson's disease: False association or etiologic clue? Neurology 45 (1995), 1041-1051.
55. P.A. Newhouse and J.R. Hughes, The role of nicotine and nicotinic mechanisms in neuropsychiatric disease, Br J Addict 86 (1991), 521-526.
56. A. Nordberg, Human nicotinic receptors - Their role in aging and dementia, Neurochem Int 25 (1994), 93-97.
57. A. Nordberg, Neuroreceptor changes in Alzheimer disease, Cerebrovasc Brain Metab Rev 4 (1992), 303-328.
58. A. Nordberg, Nicotinic receptor abnormalities of Alzheimer's disease: Therapeutic implications, Biol Psychiatry 49 (2001), 200-210.
59. A. Nordberg, A. Adem and L.e.a. Nilsson, Heterogeneous Cholinergic Nicotinic Receptors in the CNS, Springer-Verlag, New York, 1988.
60. A. Nordberg, I. Alafuzoff and B. Winblad, Nicotinic and muscarinic subtypes in the human brain: Changes with aging and dementia, J Neurosci Res 31 (1992), 103-111.
61. A. Nordberg and B. Winblad, Reduced number of (3H)nicotoine and (3H)acetylcholine binding sites in the frontal cortex of Alzheimer brains, Neurosci Lett 21 (1986), 115-119.
62. A. Ott, A.J. Slooter, A. Hofman, F. van Harskamp, J.C. Witteman, C. Van Broeckhoven, C.M. van Duijn and M.M. Breteler, Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: The Rotterdam Study, Lancet 351 (1998), 1840-1843.
63. J.R. Pauly, Nicotinic Cholinergic Receptor Deficits in Alzheimer's Disease: Where's the smoke? J Alz Dis 1 (1999), 221-230.
64. J.H. Peng, L. Lucero, J. Fryer, J. Herl, S.S. Leonard and R.J. Lukas, Inducible, heterologous expression of human alpha7-nicotinic acetylcholine receptors in a native nicotinic receptor-null human clonal line, Brain Res 825 (1999), 172-179.
65. X. Peng, V. Gerzanich, R. Anand, P.J. Whiting and J. Lindstrom, Nicotine-induced increase in neuronal nicotinic receptors results from a decrease in the rate of receptor turnover, Mol Pharmacol 46 (1994), 523-530.
66. E. Perry, C. Martin-Ruiz, M. Lee, M. Griffiths, M. Johnson, M. Piggott, V. Haroutunian, J.D. Buxbaum, J. Nasland, et al., Nicotinic receptor subtypes in human brain aging, Alzheimer and Lewy body diseases, Eur J Pharmacol 393 (2000), 215-222.
67. E.K. Perry, J.A. Court, S. Lloyd, M. Johnson, M.H. Griffiths, D. Spurden, M.A. Piggott, J. Turner and R.H. Perry, Beta-amyloidosis in normal aging and transmitter signaling in human temporal lobe, Ann N Y Acad Sci 777 (1996), 388-392.
68. E.K. Perry, C.M. Morris, J.A. Court, A. Cheng, A.F. Fairbaim, I.G. McKeith, D. Irving, A. Brown and R.H. Perry, Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology, Neuroscience 64 (1995), 385-395.
69. E.K. Perry, C.J. Smith, J.A. Court and R.H. Perry, Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types, J Neural Transm Park Dis Dement Sect 2 (1990), 149-158.
70. D.L. Pettit, Z. Shao and J.L. Yakel, beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice, J Neurosci 21 (2001), RC120.
71. A. Potter, J. Corwin, J. Lang, M. Piasecki, R. Lenox and P.A. Newhouse, Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease, Psychopharmacology (Berl) 142 (1999), 334-342.
72. M. Prince, M. Cullen and A. Mann, Risk factors for Alzheimer's disease and dementia: A case-control study based on the MRC elderly hypertension trial, Neurology 44 (1994), 97-104.
73. R.T. Reid, M.N. Sabbagh and L.J. Thal, Does apolipoprotein E (Apo-E) genotype influence nicotinic receptor binding in Alzheimer's disease, J Neural Transm 108 (2001), 1043-1050.
74. R. Reid, M. Sabbagh, J. Corey-Bloom, P. Tiraboschi and L. Thal, Nicotinic Receptor in Dementia with Lewy Bodies: Comparisons with Alzheimer's Disease, 2000, pp. 741-446.
75. R. Reitstetter, R.J. Lukas and R. Gruener, Dependence of nicotinic acetylcholine receptor recovery from desensitization on the duration of agonist exposure, J Pharmacol Exp Ther 289 (1999), 656-660.
76. J.E. Riggs, The influence of smoking on the risk of Alzheimer's disease, Neurology 54 (2000), 777-778.
77. J.O. Rinne, T. Myllykyla, P. Lonnberg and P. Marjamaki, A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease, Brain Res 547 (1991), 167-170.
78. S.W. Rogers, L.C. Gahring, A.C. Collins and M. Marks, Age-related changes in neuronal nicotinic acetylcholine receptor subunit alpha4 expression are modified by long-term nicotine administration, J Neurosci 18 (1998), 4825-4832.
79. M.N. Sabbagh, R.T. Reid, J. Corey-Bloom, T.S. Rao, L.A. Hansen, M. Alford, E. Masliah, A. Adem, G.K. Lloyd, et al., Correlation of nicotinic binding with neurochemical markers in Alzheimer's disease, J Neural Transm 105 (1998), 709-717.
80. M.N. Sabbagh, R.T. Reid, L.A. Hansen, M. Alford and L.J. Thal, Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer's disease and dementia with Lewy bodies, J Neural Transm 108 (2001), 1149-1157.
81. B. Sahakian, G. Jones, R. Levy, J. Gray and D. Warburton, The effects of nicotine on attention, information processing, and short-term memory in patients with dementia of the Alzheimer type, Br J Psychiatry 154 (1989), 797-800.
82. A.R. Salomon, K.J. Marcinowski, R.P. Friedland and M.G. Zagorski, Nicotine inhibits amyloid formation by the beta-peptide, Biochemistry 35 (1996), 13568-13578.
83. H. Schroder, E. Giacobini, R.G. Struble, K. Zilles and A. Maelicke, Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease, Neurobiol Aging 12 (1991), 259-262.
84. H. Schroder, E. Giacobini, R.G. Struble, K. Zilles, A. Maelicke, P.G. Luiten and A.D. Strosberg, Cellular distribution and expression of cortical acetylcholine receptors in aging and Alzheimer's disease, Ann N Y Acad Sci 640 (1991), 189-192.
85. J. Semba, R. Miyoshi and S. Kito, Nicotine protects against the dexamethasone potentiation of kainic acid-induced neurotoxicity in cultured hippocampal neurons, Brain Res 735 (1996), 335-338.
86. B.M. Sharp and H.S. Beyer, Rapid desensitization of the acute stimulatory effects of nicotine on rat plasma adrenocorticotropin and prolactin, J Pharmacol Exp Ther 238 (1986), 486-491.
87. B.M. Sharp, H.S. Beyer, A.S. Levine, J.E. Morley and K.M. McAllen, Attenuation of the plasma prolactin response to restraint stress after acute and chronic administration of nicotine to rats, J Pharmacol Exp Ther 241 (1987), 438-442.
88. S. Shimohama, Nicotine agonists prevent neuronal cell death by glutamate and amyloid beta protein, Neurobiology of Aging 17 (1996), S40.
89. S. Shimohama, A. Akaike and J. Kimura, Nicotine-induced protection against glutamate cytotoxicity. Nicotinic cholinergic receptor-mediated inhibition of nitric oxide formation, Ann N Y Acad Sci 777 (1996), 356-361.
90. H.N. Siegel and R.J. Lukas, Nicotinic agonists regulate alpha-bungarotoxin binding sites of TE671 human medulloblastoma cells, J Neurochem 50 (1988), 1272-1278.
91. I.N. Singh, G. Sorrentino, D.S. Sitar and J.N. Kanfer, (-)Nicotine inhibits the activation of phospholipases A2 and D by amyloid beta peptide, Brain Res 800 (1998), 275-281.
92. D.L. Sparks, T.G. Beach and R.J. Lukas, Immunohistochemical localization of nicotinic beta2 and alpha4 receptor subunits in normal human brain and individuals with Lewy body and Alzheimer's disease: Preliminary observations, Neurosci Lett 256 (1998), 151-154.
93. K. Sugaya, E. Giacobini and V.A. Chiappinelli, Nicotinic acetylcholine receptor subtypes in human frontal cortex: Changes in Alzheimer's disease, J Neurosci Res 27 (1990), 349-359.
94. A. Svensson, U. Warpmen, E. Hellstrom-Lindahl, et al., Nicotinic Receptors, Muscarinic Receptors and Choline Acetyltransferase Activity in the Temporal Cortex of Alzheimer Patient with Differing Apoliproprotein Genotypes, 232 (1997), 37-40.
95. R.D. Terry, E. Masliah, D.P. Salmon, N. Butters, R. DeTeresa, R. Hill, L.A. Hansen and R. Katzman, Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment, Ann. Neurol 30 (1991), 572-580.
96. S.L. Tyas, J.J. Koval and L.L. Pederson, Does an interaction between smoking and drinking influence the risk of Alzheimer's disease? Results from three Canadian data sets, Stat Med 19 (2000), 1685-1696.
97. S.L. Tyas, J. Manfreda, L.A. Strain and P.R. Montgomery, Risk factors for Alzheimer's disease: a population-based, longitudinal study in Manitoba, Canada, International Journal of Epidemiology 30 (2001), 590-597.
98. J. Ulrich, G. Johannson-Locher, W.O. Seiler and H.B. Stahelin, Does smoking protect from Alzheimer's disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history, Acta Neuropathol (Berl) 94 (1997), 450-454.
99. C.M. van Duijn, L.M. Havekes, C. Van Broeckhoven, P. de Knijff and A. Hofman, Apolipoprotein E genotype and association between smoking and early onset Alzheimer's disease, BMJ 310 (1995), 627-631.
100. C.M. van Duijn and A. Hofman, Relation between nicotine intake and Alzheimer's disease, BMJ 302 (1991), 1491-1494.
101. H.X. Wang, L. Fratiglioni, G.B. Frisoni, M. Viitanen and B. Winblad, Smoking and the occurrence of Alzheimer's disease: Cross-sectional and longitudinal data in a population-based study, Am J Epidemiol 149 (1999), 640-644.
102. H.Y. Wang, D.H. Lee, M.R. D'Andrea, P.A. Peterson, R.P. Shank and A.B. Reitz, beta-Amyloid (1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology, J Biol Chem 275 (2000), 5626-5632.
103. U. Warpman and A. Nordberg, Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains, Neuroreport 6 (1995), 2419-2423.
104. A. Wevers and H. Schroder, Nicotinic acetylcholine receptors in Alzheimer's disease, J Alz Dis 1 (1999), 207-219.
105. H.K. White and E.D. Levin, Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease, Psychopharmacology (Berl) 143 (1999), 158-165.
106. P.J. Whitehouse and R.N. Kalaria, Nicotinic receptors and neurodegenerative dementing diseases: Basic research and clinical implications, Alzheimer Dis Assoc Disord 9 (Suppl 2) (1995), 3-5.
107. A.L. Wilson, L.K. Langley, J. Monley, T. Bauer, S. Rottunda, E. McFalls, C. Kovera and J.R. McCarten, Nicotine patches in Alzheimer's disease: Pilot study on learning, memory, and safety, Pharmacol Biochem Behav 51 (1995), 509-514.
108. S. Wonnacott, The paradox of nicotine acetylcholine recetpor upregulation by nicotine, Trends Phar Sci 11 (1990), 216-219.
109. M.R. Zamani, Y.S. Allen, G.P. Owen and J.A. Gray, Nicotine modulates the neurotoxic effect of beta-amyloid protein(25-35) in hippocampal cultures, Neuroreport 8 (1997), 513-517.